Your browser doesn't support javascript.
loading
Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases.
Gingipalli, Lakshmaiah; Block, Michael H; Bao, Larry; Cooke, Emma; Dakin, Les A; Denz, Christopher R; Ferguson, Andrew D; Johannes, Jeffrey W; Larsen, Nicholas A; Lyne, Paul D; Pontz, Timothy W; Wang, Tao; Wu, Xiaoyun; Wu, Allan; Zhang, Hai-Jun; Zheng, Xiaolan; Dowling, James E; Lamb, Michelle L.
Afiliação
  • Gingipalli L; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA. Electronic address: lakshmaiah.gingipalli@astrazeneca.com.
  • Block MH; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Bao L; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Cooke E; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Dakin LA; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Denz CR; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Ferguson AD; Structure and Biophysics, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Johannes JW; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Larsen NA; Structure and Biophysics, Discovery Sciences, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Lyne PD; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Pontz TW; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Wang T; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Wu X; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Wu A; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Zhang HJ; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Zheng X; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Dowling JE; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA.
  • Lamb ML; Chemistry, Oncology, IMED Biotech Unit, AstraZeneca, Boston, USA; 35 Gatehouse Drive, Waltham, MA 02451, USA.
Bioorg Med Chem Lett ; 28(8): 1336-1341, 2018 05 01.
Article em En | MEDLINE | ID: mdl-29559278
The design and synthesis of a novel series of 2,6-disubstituted pyrazine derivatives as CK2 kinase inhibitors is described. Structure-guided optimization of a 5-substituted-3-thiophene carboxylic acid screening hit (3a) led to the development of a lead compound (12b), which shows inhibition in both enzymatic and cellular assays. Subsequent design and hybridization efforts also led to the unexpected identification of analogs with potent PIM kinase activity (14f).
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazinas / Caseína Quinase II / Inibidores de Proteínas Quinases / Proteínas Proto-Oncogênicas c-pim-1 Limite: Humans Idioma: En Revista: Bioorg Med Chem Lett Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pirazinas / Caseína Quinase II / Inibidores de Proteínas Quinases / Proteínas Proto-Oncogênicas c-pim-1 Limite: Humans Idioma: En Revista: Bioorg Med Chem Lett Ano de publicação: 2018 Tipo de documento: Article